Critical Role for 24-Hydroxylation in Homeostatic Regulation of Vitamin D Metabolism

Zhinous Shahidzadeh Yazdi, Elizabeth A. Streeten, Hilary B. Whitlatch,

May E. Montasser, Amber L. Beitelshees, and Simeon I. Taylor

Department of Medicine

Division of Endocrinology, Diabetes, and Nutrition

University of Maryland School of Medicine

Baltimore, MD, USA

Corresponding author: Simeon I. Taylor, MD, PhD, Department of Medicine, University of

Maryland School of Medicine, Baltimore, MD 21201, USA

Telephone number: +1 301 980 5272

Email: staylor2@som.umaryland.edu

Conflict-of-interest statement: SIT serves as a consultant for Ionis Pharmaceuticals and receives
an inventor's share of royalties from NIDDK for metreleptin as a treatment for generalized
lipodystrophy. EAS, MEM, and HBW receive research support (unrelated to this project) from
the Regeneron Genetics Center. ZSY and ALB have no conflicts to disclose.

Trial registration: NCT02891954 (clinicaltrials.gov)

Funding: National Institute of Diabetes, Digestive, and Kidney Diseases: R01DK118942,
R01DK118924-02S1, and T32DK098107

ABSTRACT

The body has evolved effective homeostatic mechanisms to maintain free levels of Ca^{+2} and

1,25-dihydroxyvitamin D [1,25(OH)$_2$D] within narrow physiological ranges. The literature

documents critical contributions of PTH to this homeostatic regulation. We developed a

mechanistic mathematical model documenting an important contribution from homeostatic

regulation of 24-hydroxylase activity. Data on vitamin D (VitD) metabolite levels were obtained

from a clinical trial conducted in healthy participants with baseline total 25-hydroxyvitamin D

[25(OH)D] levels ≤20 ng/mL. The trial was designed as a crossover trial in which participants

were studied before and after receiving VitD3 supplementation (≥4-6 weeks) to achieve total

25(OH)D levels >30 ng/mL. VitD3 supplementation significantly increased mean levels of

25(OH)D by 2.7-fold and 24,25-dihydroxyvitamin D [24,25(OH)$_2$D] by 4.3-fold. In contrast,

mean levels of PTH, FGF23, and 1,25(OH)$_2$D did not change in response to VitD3

supplementation. Mathematical modeling suggested that 24-hydroxylase activity was maximal

for 25(OH)D levels ≥50 ng/mL and achieved a minimum (~90% suppression) when 25(OH)D

levels were <10-20 ng/mL. Suppression of 24-hydroxylase is triggered by mild-moderate VitD

deficiency and is predicted to sustain physiological levels of 1,25(OH)$_2$D by suppressing

metabolic clearance of 1,25(OH)$_2$D. VitD metabolite ratios [e.g., 1,25(OH)$_2$D/24,25(OH)$_2$D]

provide useful indices demonstrating that the body has triggered homeostatic regulation to

compensate for limited availability of VitD. Thus, suppression of 24-hydroxylase activity

provides a first line of defense protecting against VitD deficiency. In severe VitD deficiency,

when this first line of defense has been maximally deployed, the body triggers secondary

hyperparathyroidism, thereby providing a second line of defense.

INTRODUCTION

Notwithstanding recent controversies about medical uses of vitamin D (VitD) supplements (1-4),

it is well established that VitD plays an essential role in mediating absorption of dietary calcium

in the intestine (5). 25-hydroxyvitamin D [25(OH)D] is synthesized in the liver in a reaction

catalyzed by 25-hydroxylase (CYP2R1). 25(OH)D can undergo two alternative fates: 1α-

hydroxylation by CYP27B1 to generate $1,25(OH)_2D$ (the biologically active species) or 24-

hydroxylation by CYP24A1 leading to 24,25-dihydroxyvitamin D [$24,25(OH)_2D$] (6). Current

clinical practice guidelines recommend measuring total circulating levels of 25(OH)D to assess

clinical VitD status (7).

Total levels of 25(OH)D vary widely over a greater than tenfold range, depending on nutritional

status, age, body weight, exposure to ultraviolet light, and levels of vitamin D binding protein

(VDBP). Levels of $24,25(OH)_2D$ generally vary in parallel with 25(OH)D (8, 9), consistent with

the fact that 25(OH)D serves as the biosynthetic precursor of $24,25(OH)_2D$. In marked contrast,

levels of $1,25(OH)_2D$ are maintained in a relatively narrow physiological range despite wide

variation in availability of 25(OH)D (8, 10). We have applied mathematical modeling to

investigate homeostatic mechanisms that regulate VitD metabolism so effectively. The negative

feedback loop involving PTH is often cited as a key factor contributing to maintenance of

$1,25(OH)_2D$ in a narrow physiological range (7). Tang et al. (11) have suggested that the balance

between 1α-hydroxylation and 24-hydroxylation may also contribute. Our mathematical model

provides quantitative estimates of the magnitude of homeostatic regulation of 24-hydroxylation,

thereby confirming the importance of this mechanism. We discuss the implications of these

insights for diagnosis and treatment of VitD deficiency. Furthermore, we discuss a clinically

informative approach to assess VitD status based on calculated ratios of VitD metabolites. Tang

et al. (11) previously suggested that the $1,25(OH)_2D/24,25(OH)_2D$ ratio provides a more relevant

index for assessment of VitD status compared to measuring total levels of 25(OH)D in serum or

plasma. In this study, we calculated and assessed three VitD metabolite ratios (12-15) among

which we concluded that $1,25(OH)_2D/24,25(OH)_2D$ and $25(OH)D/1,25(OH)_2D$ ratios may

provide the most clinically relevant information regarding VitD status.

METHODS

This study ("Vitamin D Sub-study") was part of our ongoing "Genetics of Response to

Canagliflozin (GRC)" clinical trial (clinicaltrials.gov Identifier: NCT02891954) in healthy

volunteers recruited from the Old Order Amish population in Lancaster PA, who are non-

Hispanic white people. Although participants were excluded from the parent study if their

25(OH)D level was ≤20 ng/mL, these VitD deficient individuals were eligible to participate in

the VitD Sub-study, which investigated the effects of VitD3 supplements on canagliflozin-

triggered changes in the serum phosphorus/FGF23/$1,25(OH)_2D$/PTH axis. Participants were

required to meet all other inclusion/exclusion criteria for the parent study (8).

We screened 24 healthy volunteers from September 2019 to July 2021 and enrolled 19

individuals with 25(OH)D levels ≤20 ng/mL who were otherwise eligible to participate in the

parent GRC study. Details of demographics, baseline characteristics, recruitment, and disposition

are reported elsewhere (8). Because of interruptions and delays associated with the COVID-19

pandemic, we did not complete our plan to study 25 research participants. The study was funded

by a one-year Administrative Supplement from the NIH Office of Dietary Supplements; funding

was not available to extend the clinical trial to enroll and study more participants after the end of

the funding period for the Administrative Supplement. We analyzed data after eleven

participants (four females and seven males) completed the entire study protocol. Mean age for

these eleven research participants was 48.0±3.2 years; mean BMI was 29.0±1.2 kg/m^2; and mean

eGFR was 98.5±4.0 mL/min/1.73 m^2 (8).

The Endocrine Society's clinical practice guidelines proposed thresholds of 25(OH)D ≤20

ng/mL (≤50 nmol/L) for VitD deficiency, 21-29 ng/mL (51-74 nmol/L) for VitD insufficiency,

and ≥ 30 ng/mL (≥75 nmol/L) for VitD sufficiency (7). We applied The Endocrine Society's

definition of VitD deficiency (≤20 ng/mL) as a key inclusion criterion for this sub-study and

applied the definition of VitD sufficiency (≥30 ng/mL) as the criterion for adequacy of VitD3

supplementation.

VitD3 supplementation protocol

VitD-deficient participants completed canagliflozin challenge #1 and then received VitD3

capsules (Bio-Tech Pharmacal; Fayetteville, AR) in doses of either 50,000 IU per week for

participants with BMI <30 kg/m^2 or 50,000 IU twice a week for participants with BMI ≥30 kg/m

for four weeks, followed by a second 25(OH)D measurement a week after completion of the

four-week VitD3 supplementation protocol (8). If screening serum 25(OH)D levels (Quest

Diagnostics) were <30 ng/mL, high-dose VitD3 supplementation was continued. Once screening

25(OH)D (Quest Diagnostics) levels were confirmed to be ≥30 ng/mL, maintenance-dose VitD3

supplementation (1000 IU/d or 2000 IU/d for BMI <30 kg/m^2 or BMI ≥30 kg/m^2, respectively)

was continued until completion of canagliflozin challenge #2.

Clinical chemistry

Blood samples obtained at home visits were collected in test tubes as appropriate for each assay

(8). Assays for baseline levels of plasma PTH, serum $1,25(OH)_2D$, and serum $25(OH)D$ were

conducted at Quest Diagnostics. Total plasma levels of $25(OH)D$ and $24,25(OH)_2D$ were

assessed using LC/MS/MS assays conducted by Heartland Assays (Ames, IA). Quest's serum

$25(OH)D$ levels were used to determine eligibility for the VitD Sub-study. Heartland's plasma

$25(OH)D$ levels were used to assess the response to VitD3 supplements. We have reported

$25(OH)D$ and $24,25(OH)_2D$ in ng/mL and $1,25(OH)_2D$ in pg/mL. Multiplication by a factor of

2.49 can be used to convert from ng/mL to nmol/L. Mean levels for $25(OH)D$ before and after

VitD3 supplementation, were identical in assays conducted by Quest Diagnostics and Heartland

Assays (8).

Mathematical Modeling

We developed a mathematical model to analyze relationships among $25(OH)D$, $1,25(OH)_2D$, and

$24,25(OH)_2D$. Details are provided in the Results section. The parameters of the model were

estimated by an iterative trial and error approach to fit the clinical trial data. We assessed the

model's goodness of fit by calculating sums of squared errors as described in detail in the legend

for Table 1.

Statistics

A two-sided p-value <0.05 (paired t-test) was taken as the threshold for statistical significance

without any correction for multiple comparisons. We pooled all the data before and after VitD3

supplementation for graphing total levels of $1,25(OH)_2D$ and $24,25(OH)_2D$ as a function of total

levels of $25(OH)D$. Correlation coefficients were calculated using software provided in Excel.

Study approval

The Clinical Trial Protocol was approved by the University of Maryland Baltimore Institutional

Review Board (FWA00007145). Informed consent was obtained from all participants.

RESULTS

We designed a clinical trial (NCT02891954) to investigate pharmacodynamic nutrient-drug

interactions between VitD and an SGLT2 inhibitor (canagliflozin) (8). The study included two

canagliflozin challenge tests to assess pharmacodynamic responses to canagliflozin. The first

canagliflozin challenge was conducted at a time when research participants were VitD deficient

[screening 25(OH)D levels ≤20 ng/mL] and the second after participants had received VitD3

supplements [screening 25(OH)D levels ≥30 ng/mL]. Data on recruitment, disposition, and

primary outcomes are summarized elsewhere (8). Herein we report analysis of data for the

effects of VitD3 supplementation on homeostatic regulation of VitD metabolite levels. This

analysis focuses on mathematical modeling of changes in VitD metabolite levels in response to

VitD3 supplements.

Interrelationships among $1,25(OH)_2D$, $24,25(OH)_2D$, and $25(OH)D$.

As reported elsewhere, mean (±SEM) total plasma levels of both 25(OH)D and $24,25(OH)_2D$

increased significantly in response to VitD3 supplementation: from 16.5±1.6 to 44.3±5.5 ng/mL

(p=0.0006) for 25(OH)D and from 1.0±0.1 to 4.3±0.6 ng/mL (p=0.0002) for $24,25(OH)_2D$ (8).

We observed consistent increases in total levels of 25(OH)D and $24,25(OH)_2D$ (Figs. 1A and

1B). In contrast, mean total plasma levels of $1,25(OH)_2D$ did not change in response to VitD3

supplements (43.8±3.6 pg/mL versus 44.9±4.1 pg/mL) (Fig. 1C) (8). This observation provides

strong evidence of the effectiveness of homeostatic mechanisms regulating levels of

1,25(OH)$_2$D. Therefore, we conducted exploratory analyses to further investigate physiological

mechanisms mediating this homeostatic regulation.

For this analysis, we pooled data on VitD metabolites – from before and after VitD3

supplementation (Fig. 2). Although there was no significant correlation between total plasma

levels of 1,25(OH)$_2$D and 25(OH)D (Fig. 2A), total plasma levels of 24,25(OH)$_2$D increased as a

function of total plasma 25(OH)D levels (Fig. 2B).

A critical role for regulation of 24-hydroxylase activity in homeostatic regulation of 1,25(OH)$_2$D

We considered possible mechanisms that might contribute to the observed sigmoid shape of the

curve relating total 24,25(OH)$_2$D levels to total 25(OH)D levels (Fig. 2B). If the 24-hydroxylase

enzyme (CYP24A1) followed simple Michaelis-Menten kinetics, one might have predicted that

the relationship between plasma levels of 24,25(OH)$_2$D and 25(OH)D would have been

described by a hyperbola (Fig. 3A, solid curve) rather than a sigmoid curve (Fig. 3A, dashed

curve). The observed sigmoid curve approaches an asymptote at high levels of 25(OH)D – most

likely a reflection of the saturability of the 24-hydroxylase enzyme (CYP24A1). What can

explain the relative underproduction of 24,25(OH)$_2$D at low levels of 25(OH)D as compared to

what would have been predicted by simple Michaelis-Menten kinetics? As suggested by others

(11, 16), we hypothesized that expression of 24-hydroxylase enzyme is regulated, with low 24-

hydroxylase activity when 25(OH)D levels are low and higher 24-hydroxylase activity when

25(OH)D levels are high. We applied mathematical modeling (see below) to provide quantitative

estimates of the relationship between activity of the 24-hydroxylase enzyme and 25(OH)D levels

(Fig. 3C). Our model suggests that 24-hydroxylase activity achieves a maximum when 25(OH)D

levels exceed 50 ng/mL. In contrast, VitD deficiency is associated with suppression of 24-

hydroxylase activity– achieving a minimum corresponding to ~90% suppression of 24-

hydroxylase activity when 25(OH)D levels are less than 10-20 ng/mL. As summarized below,

our mathematical model provides estimates of 24-hydroxylase activity as a function of 25(OH)D

levels (Fig. 3C).

Mathematical model of sigmoid curve interrelating levels 24,25(OH)$_2$D and 25(OH)D.

The observed sigmoid curve expressing the concentration of total 24,25(OH)$_2$D as a function of

total 25(OH)D can be fit by an equation with the form of Equation (1):

(1) $S(24,25) = \dfrac{(\frac{W24}{L24})e^{aS(25)}}{1+\frac{e^{aS(25)}}{L24}}$

where S(25) and S(24,25) represent levels of 25(OH)D and 24,25(OH)$_2$D, respectively; W_{24} and

L_{24} represent analogs of the maximal velocity and Michaelis-Menten constant for 24-

hydroxylase enzyme with 25(OH)D as substrate; α is a model parameter to facilitate fitting the

equation to the observed data. Equation (1) provides a good fit to the observed data as shown by

the graph plotting total levels of 24,25(OH)$_2$D as a function of 25(OH)D (Fig. 2B). Goodness of

fit is evidenced by the fact that the sum of the squared errors (SSE) is small relative to the total

sum of the squares about the mean (SST): SSE/SST = 0.078 (Table 1).

The model assumes that 24,25(OH)$_2$D is cleared by a first order process with a rate constant of

$m(24,25)$ [Equation (1a)]:

(1a) $Rate\ of\ clearance\ of\ 24,25(OH)_2D = m(24,25)\dfrac{(\frac{W24}{L24})e^{aS(25)}}{1+\frac{e^{aS(25)}}{L24}}$

We hypothesized that the 24-hydroxylase enzyme follows Michaelis-Menten kinetics as

described by Equation (2):

$$(2)\ Production\ of\ 24,25(OH)_2D = \frac{V24 \times h \times S(25)}{K24 + S(25)}$$

where $S(25)$ represents the level of 25(OH)D; V_{24} and K_{24} represent the maximal velocity and

Michaelis-Menten constant for 24-hydroxylase enzyme with 25(OH)D as substrate. h is a

variable function of $S(25)$ that represents 24-hydroxylase activity as a fraction of the maximally

induced level of the enzyme observed when 25(OH)D levels are high.

At steady state, the rate of production of 24,25(OH)$_2$D [Equation (2)] is equal to the rate at which

24,25(OH)$_2$D is cleared [Equation (1a)]. Accordingly, the value of h can be calculated by

Equation (3):

$$(3)\ h = m(24,25) \frac{(\frac{W24}{L24})e^{aS(25)}}{1 + \frac{e^{aS(25)}}{L24}} \div \frac{V24 \times S(25)}{K24 + S(25)}$$

Genetic evidence demonstrates the critical role of CYP24A1-mediated 24-hydroxylation in

inactivation of 1,25(OH)$_2$D (17, 18). Homozygosity for loss of function mutations in *CYP24A1*

has been reported to cause hypercalcemia – presumably due to excessive levels of 1,25(OH)$_2$D.

Since CYP24A1 catalyzes 24-hydroxylation of both 25(OH)D and 1,25(OH)$_2$D, we modified

Equation (1a) to yield Equation (4):

$$(4)\ Rate\ of\ clearance\ of\ 1,25(OH)_2D = m(1,25) \frac{(\frac{W1,25}{L1,25})e^{aS(1,25)}}{1 + \frac{e^{aS(1,25)}}{L1,25}}$$

where $S(1,25)$ represents the level of 1,25(OH)₂D; $W_{1,25}$ and $L_{1,25}$ represent analogs of the

maximal velocity and Michaelis-Menten constant for 24-hydroxylase enzyme with 1,25(OH)₂D

as substrate; α is a model parameter that facilitates fitting the equation to the observed data; and

$m(1,25)$ is a first-order rate constant analogous to $m(24,25)$ in Equation (1a).

Further, we hypothesize that CYP27B1-mediated 1α-hydroxylation of 25(OH)D follows

Michaelis-Menten kinetics:

$$(5)\ Production\ of\ 1,25(OH)_2 D = \frac{V1 \times S(25)}{K1 + S(25)}$$

where V_1 and K_1 represent the maximal velocity and Michaelis-Menten constant for 1α-

hydroxylase with 25(OH)D as substrate. Under steady state conditions, the rates of production

and metabolic clearance of 1,25(OH)₂D are equal. Thus, we can combine Equations (4) and (5)

to yield Equation (6):

$$(6)\ \frac{V1 \times S(25)}{K1 + S(25)} = m(1,25) \frac{(\frac{W_{1,25}}{L_{1,25}}) e^{aS(1,25)}}{1 + \frac{e^{aS(1,25)}}{L_{1,25}}}$$

Solving for $S(1,25)$, we obtain Equation (7):

$$(7)\ S(1,25) = \{Ln[S(25)] - Ln\left[m_{1,25} + \frac{S(25)}{K_1}\left(m_{1,25} - \frac{V_1}{W_{1,25}}\right)\right] - Ln\frac{W_{1,25}K_1}{L_{1,25}V_1}\}/a$$

Equation (7) correctly predicts that 1,25(OH)₂D levels are not correlated with 25(OH)D levels

(Fig. 2A). Indeed, the sum of the squared errors (SSE) is approximately equal to the total sum of

the squares about the mean (SST): SSE/SST = 1.04 (Table 1). Furthermore, the ratio of

SSR/SST = 0.094 suggests that a horizontal line with 1,25(OH)₂D=44.4 pg/mL (i.e., the mean

level of 1,25(OH)₂D) provides a good fit for the observed data. Interestingly, the modeled curve

predicts that levels of 1,25(OH)₂D begin to decrease slightly for levels of 25(OH)D less than a

cutoff of ~15-20 ng/mL. This "fall-off" may possibly be related to the fact that the model does

not account for development of secondary hyperparathyroidism. If the model specified that low

levels of 25(OH)D would trigger increased secretion of PTH, it would likely be possible for the

model to maintain constant levels of $1,25(OH)_2D$ even for lower levels of 25(OH)D.

The data points in Fig. 2A demonstrate substantial "scatter" around the modeled curve. However,

VitD binding protein (VDBP) levels are reported to vary over an approximately threefold range

(19). This 3-fold variation in VDBP levels could account for the observed 3.4-fold range of total

levels of $1,25(OH)_2D$ observed in this study, which in turn could account for the observed scatter

for data points in the plot of total levels of $1,25(OH)_2D$ versus total levels of 25(OH)D (Fig. 2A).

Modeling VitD Metabolite Ratios

Tang et al. (11) proposed that the ratio of $1,25(OH)_2D/24,25(OH)_2D$ provides an improved

assessment of clinical VitD status with a ratio ≥ 51 suggesting "VitD deficiency" and a ratio of

35-50 suggesting "VitD insufficiency". We applied our mathematical model to predict the shape

of the curve expressing Tang's VitD metabolite ratio $(1,25(OH)_2D/1,24(OH)_2D)$ as a function of

total levels of 25(OH)D. Our modeled curve (Fig. 4A) closely resembles the curve included in

the publication by Tang et al. (11). Based on our modeled curve, the cutoffs proposed by Tang et

al. correspond to total 25(OH)D levels of ~17 ng/mL for "VitD deficiency" and ~21 ng/mL for

"VitD insufficiency".

Furthermore, our mathematical model provides a good fit to the observed data as shown by the

graph plotting total levels of $1,25(OH)_2D/24,25(OH)_2D$ as a function of 25(OH)D (Fig. 4A).

Two other VitD metabolite ratios have been proposed in the literature: $1,25(OH)_2D/25(OH)D$

(15) and $24,25(OH)_2D/25(OH)D$ (12-14, 20, 21). Our mathematical model predicts that the

25(OH)D/1,25(OH)$_2$D ratio (i.e., the reciprocal of the 1,25(OH)$_2$D/25(OH)D ratio proposed in

the literature (15)) is a near-linear function of 25(OH)D levels (Fig. 5A); the graph of the

24,25(OH)$_2$D/25(OH)D ratio versus 25(OH)D is predicted to be a sigmoid curve (Fig. 5B). The

modeled curves for all three VitD metabolite ratios provided good fits to observed data

[SSE/SST ratios of 0.49-0.52 (Table 1)].

As noted in the literature, ratios of VitD metabolites are relatively independent of inter-

individual variation in VDBP levels (20). For example, the following equations demonstrate that

the ratio of [1,25(OH)$_2$D]/[24,25(OH)$_2$D] is independent of VDBP levels:

$$(8)\ [1,25(OH)_2D]_{total} \approx [1,25(OH)_2D]_{free} \times VDBP_{total} \times K_{1,25}$$

$$(9)\ [24,25(OH)_2D]_{total} \approx [24,25(OH)_2D]_{free} \times VDBP_{total} \times K_{24,25}$$

$$(10)\ \frac{[1,25(OH)_2D]_{total}}{[24,25(OH)_2D]_{total}} \approx \frac{[1,25(OH)_2D]_{free}}{[24,25(OH)_2D]_{free}} \times \frac{K_{1,25}}{K_{24,25}}$$

For example, when the $\frac{[1,25(OH)_2D]_{total}}{[24,25(OH)_2D]_{total}}$ ratio is plotted as a function of total levels of 25(OH)D,

this represents a graph of a VDBP-independent variable on the y-axis and a VDBP-dependent

variable on the x-axis (Fig. 4A). In contrast, the graph of $\frac{[1,25(OH)_2D]_{total}}{[24,25(OH)_2D]_{total}}$ as a function of

$\frac{[25(OH)D]_{total}}{[1,25(OH)_2D]_{total}}$ plots VDBP-independent variables on both axes (Figs. 4B). This approach

minimized the contribution of inter-individual variation in VDBP levels, thereby minimizing

"scatter" of points in the graph (Fig. 4B). When $\frac{[1,25(OH)2D]_{total}}{[24,25(OH)2D]_{total}}$ was plotted as a function of

$\frac{[25(OH)D]_{total}}{[1,25(OH)2D]_{total}}$, the absolute value of the Spearman correlation coefficient was quite high (r_S = -

0.94; p= 10^{-10}) (Fig. 4B). In contrast, the absolute value of the Spearman correlation coefficient

was lower (r_S = -0.83; p=2.2x10^{-6}) when $\frac{[1,25(OH)2D]_{total}}{[24,25(OH)2D]_{total}}$ was plotted as a function of total levels

of 25(OH)D (Fig. 4A).

Case studies exemplifying impact of VitD metabolite ratios as diagnostic criteria

Data from three participants in our clinical trial illustrate the potential value of implementing a

precision diagnostics approach, which implicitly corrects for variation in levels of VDBP. The

three patients had similar levels of total 25(OH)D, ranging from 10.8 - 12.3 ng/mL (Table 2).

Because all three participants' total plasma 25(OH)D levels were substantially less than 20

ng/mL at baseline, the Endocrine Society's clinical practice guidelines would diagnose all three

of them as being VitD deficient and would recommend treatment for all three with VitD

supplements. The three participants' plasma PTH levels ranged from 29-62 pg/mL, which falls

within Quest Diagnostics' reference range (16 - 77 pg/mL). When VitD3 supplements were

administered to participants #6 and #9, PTH levels exhibited a small, insignificant increase (+3

to +5%). In contrast, VitD3 supplements led to substantial suppression of PTH in participant #11

(-34%) – suggesting that participant #11 exhibited secondary hyperparathyroidism. The presence

of secondary hyperparathyroidism suggests that participant #11 would likely benefit from

treatment with VitD supplements. Interestingly, participant #9 had a normal baseline

1,25(OH)$_2$D/24,25(OH)$_2$D ratio of 20 suggesting that participant #9 was VitD sufficient (11).

Participant #6 exhibited a baseline 1,25(OH)$_2$D/24,25(OH)$_2$D ratio of 41, consistent with "VitD

insufficiency" according to criteria proposed by Tang et al. (11). In contrast, participant #11

exhibited an elevated baseline 1,25(OH)$_2$D/24,25(OH)$_2$D level of 110 – the highest value

observed in our clinical trial. Indeed, according to Tang et al., a 1,25(OH)$_2$D/24,25(OH)$_2$D ratio

>100 identifies individuals with an increased likelihood of exhibiting high levels of plasma PTH

(11). Individual-level data on levels of VitD metabolite levels and VitD metabolite ratios are

summarized graphically in Fig. S1.

DISCUSSION

Claude Bernard noted in the 19th century that "*stability of the internal environment (milieu*

intérieur) is a condition for a free and independent life" (22). Later, in the early 20th century,

Walter B. Cannon coined the term "*homeostasis*" to describe mechanisms that maintain the

stability of the *milieu intérieur* (22, 23). Because of the critical importance of calcium in many

biological processes, the "*Wisdom of the Body*" has evolved multiple homeostatic mechanisms to

maintain free serum Ca^{+2} levels within a narrow physiological range. Because VitD plays a

critical role in mechanisms mediating intestinal absorption of dietary Ca^{+2}, homeostatic

mechanisms have evolved to maintain stable levels of both free Ca^{+2} and free $1,25(OH)_2D$ within

relatively narrow physiological ranges. For example, as noted in The Endocrine Society's

clinical practice guidelines, VitD deficiency induces increased secretion of parathyroid hormone

(PTH) (7), which increases expression of 1α-hydroxylase enzyme in the kidney (6, 24), thereby

enhancing biosynthesis of $1,25(OH)_2D$ and increasing intestinal absorption of Ca^{+2} (5). In

addition to the beneficial actions of secondary hyperparathyroidism, elevated levels of PTH also

exert adverse effects on bone health. The Endocrine Society's clinical practice guidelines note

that VitD-induced secondary hyperparathyroidism has an adverse impact on bone health by

increasing "*osteoclastic activity thereby creating local foci of bone weakness, which causes a*

generalized decrease in bone mineral density, resulting in osteopenia and osteoporosis" (7).

Two lines of defense to maintain physiological levels of 1,25(OH)₂D

Based on our study's inclusion criteria, all our research participants met the Endocrine Society's

criterion for VitD deficiency [i.e., screening 25(OH)D ≤ 20 ng/mL]. Nevertheless, mean levels of

PTH were within normal limits and did not change when VitD3 supplements were administered

to correct the VitD deficiency. Mean PTH levels were 47.5 ± 4.8 pg/mL before and 48.4 ± 5.1

pg/mL after administration of VitD3 supplements. These data are consistent with published

evidence suggesting that mild-moderate VitD deficiency may not trigger secondary

hyperparathyroidism. In contrast, secondary hyperparathyroidism is a characteristic feature of

severe VitD deficiency [25(OH)D <10-12 ng/mL] (25-27).

Our data demonstrate the existence of another physiologic mechanism contributing to

homeostatic regulation of VitD metabolism. When VitD is in short supply, the body has at least

two options to maintain physiological levels of $1,25(OH)_2D$: (a) to increase the rate at which

25(OH)D is converted to $1,25(OH)_2D$ or (b) to decrease the rate at which $1,25(OH)_2D$ is

degraded. Our mathematical model suggests that mild-moderate VitD deficiency triggers

suppression of 24-hydroxylase activity, which is the principal enzyme mediating degradation of

$1,25(OH)_2D$ (6). Because suppression of 24-hydroxylase is triggered by mild-moderate degrees

of VitD deficiency, this mechanism provides the first line of defense against VitD deficiency.

Interestingly, viewed from a different perspective, 24-hydroxylase activity is induced in response

to high levels of 25(OH)D, which provides the major defense against VitD toxicity. In the

absence of secondary hyperparathyroidism, it is possible that mild-moderate VitD deficiency

may not indicate an absolute requirement for treatment with VitD supplements. On the other

hand, recent publications have suggested that $24,25(OH)_2D$ exerts a direct effect to promote

healing of bone fractures (28-30). In other words, whether or not mild-moderate VitD deficiency

increases the risk of bone fracture, adequate levels of $24,25(OH)_2D$ may promote healing of bone

fractures. In any case, considerable controversy exists with respect to the overall health impact of

VitD status and VitD supplementation (1-4).

Published literature demonstrates that severe VitD deficiency triggers secondary

hyperparathyroidism which induces increased 1α-hydroxylase activity thereby increasing the rate

of 1,25(OH)$_2$D biosynthesis (24, 25). Because secondary hyperparathyroidism is triggered by

severe VitD deficiency [e.g., 25(OH)D <10-12 ng/mL], this mechanism provides the second line

of defense against VitD deficiency. Because secondary hyperparathyroidism has adverse effects

on bone health, this provides a strong rationale for treatment with VitD supplements. We propose

two diagnostic terms to reflect clinical differences between these two scenarios. Sub-Clinical

VitD Deficiency describes a clinical condition when only the first line of defense (suppression of

24-hydroxylase) has been triggered. Overt VitD Deficiency describes a clinical condition when

both lines of defense are triggered (i.e., suppression of 24-hydroxylase plus secondary

hyperparathyroidism).

It is uncertain what mechanism(s) mediate homeostatic regulation of 24-hydroxylase activity.

Interestingly, expression of the *CYP24A1* gene (the gene encoding 24-hydroxylase enzyme) is

reported to be increased by 1,25(OH)$_2$D and FGF23 but decreased by PTH (31). However, mean

levels of 1,25(OH)$_2$D, FGF23, and PTH did not change in response to VitD3 supplementation

(8). Taken at face value, these observations suggest that regulation of 24-hydroxylase activity

may be mediated by factors other than levels of 1,25(OH)$_2$D, FGF23, or PTH. Nevertheless, it

remains possible that regulation of 24-hydroxylase activity is sensitive to extremely small

changes in levels of 1,25(OH)$_2$D, FGF23, or PTH, which were not detected in our study.

Furthermore, all three hormones exhibit circadian variation (32-34). Since we have obtained

blood samples at only one time of day, we cannot exclude the possibility that the relevant

biomarker(s) might require measurements of circulating levels integrated over a 24-hour period.

In any case, additional research will be required to answer this interesting question.

 Strengths and limitations

The principal limitation of this study relates to the small number of individuals who participated

in the study – in part because of challenges, interruptions, and delays due to the COVID-19

pandemic. Several strengths contributed to mitigating the limitation due to the small sample size.

By studying the same individuals before and after receiving VitD3 supplements in a crossover

study design, we were able to apply paired t-tests to assess statistical significance, which

increased statistical power to assess the impact of VitD3 supplementation (Fig. 1). Furthermore,

several of the endpoints (e.g, serum phosphorus, $1,25(OH)_2D$, PTH, and FGF23) exhibit

circadian rhythms (32-34). We minimized the impact of circadian rhythms by obtaining all blood

tests at the same time of day (7 AM). In addition, Heartland Assays specializes in applying LC-

MS-MS to measure levels of hydroxylated VitD metabolites. The use of Heartland Assays'

clinical laboratory enhanced the accuracy and reproducibility of the data. Furthermore, we are

reassured by the close similarity between our data with data previously published by Tang et al.

when the $1,25(OH)_2D/24,25(OH)_2D$ ratio was plotted as a function of the 25(OH)D level (11).

Inasmuch as the study by Tang et al. included 940 healthy army recruits, the high degree of

similarity increases our confidence that our 11 participants provided a representative sample of

healthy individuals.

Implications for clinical diagnosis of VitD deficiency

Although the Endocrine Society's clinical practice guidelines recommend a "one-size-fits-all"

approach based on measurements of total levels of 25(OH)D (7), this approach does not account

for substantial inter-individual variation in levels of VDBP that limits the applicability of a "one-

size-fits-all" approach. Whereas the usual clinical assays primarily reflect protein-bound levels

of VitD metabolites, it is the free levels (i.e., not bound to protein) that are biologically relevant

(35). This provides a strong rationale for a *precision diagnostics* approach wherein diagnostic

criteria for VitD deficiency are adjusted for each individual based on that person's circulating

levels of VitD binding proteins (i.e., VDBP and albumin). Other factors may also be relevant to

setting individualized diagnostic criteria for VitD deficiency: for example, individual setpoints

for PTH secretion, and an individual's sensitivity to biological actions of PTH (36). These

considerations raise challenging questions about how best to implement a precision diagnostics

approach to diagnose VitD deficiency and secondary hyperparathyroidism.

In the practice of clinical endocrinology, deficiency states are frequently diagnosed by

documenting the activation of compensatory homeostatic mechanisms. For example,

hypothyroidism is diagnosed by documenting elevated levels of TSH. Conversely,

hyperthyroidism is diagnosed by documenting suppression of TSH levels (37). By basing

diagnoses on whether the body's homeostatic responses have been triggered, physicians

implicitly rely on Cannon's concept of the "*wisdom of the body*" to diagnose hormonal status.

Following these precedents, one might base the diagnosis of VitD deficiency on documenting the

activation of the relevant homeostatic mechanisms – e.g., suppression of 24-hydroxylase activity.

However, it is challenging to base the diagnosis solely on measuring total $24,25(OH)_2D$ levels

because of the confounding influence of inter-individual variation in VDBP levels. The observed

threefold inter-individual variation in levels of VDBP (19) is predicted to cause a threefold inter-

individual variation in total levels of $24,25(OH)_2D$ even in individuals with identical levels of

free $24,25(OH)_2D$. Fortunately, VitD metabolite ratios are known to be independent of VDBP

levels (20). Tang et al. (11) have advocated the use of the $1,25(OH)_2D/24,25(OH)_2D$ ratio for

this purpose. As confirmed by our mathematical modeling (Fig. 4A), VitD deficiency is

associated with a dramatic increase in the $1,25(OH)_2D/24,25(OH)_2D$ ratio as a consequence of

the marked suppression of 24-hydroxylase activity induced by VitD deficiency. By providing an

index of the level of 24-hydroxylase activity, the $1,25(OH)_2D/24,25(OH)_2D$ ratio provides a

highly sensitive index of clinical VitD status. Furthermore, because of the extremely high

correlation between the $1,25(OH)_2D/24,25(OH)_2D$ ratio and the $25(OH)D/1,25(OH)_2D$ ratio

(Fig. 4B), it seems likely that the $25(OH)D/1,25(OH)_2D$ ratio might also provide a useful clinical

assessment of VitD status. This latter ratio is based on two widely available assays [25(OH)D

and $1,25(OH)_2D$] whereas the $1,25(OH)_2D/24,25(OH)_2D$ ratio requires an assay for

$24,25(OH)_2D$, which is less widely available and more expensive.

We have offered some tentative hypotheses related to the necessity of VitD supplements in overt

VitD deficiency as compared to the possible optional nature of VitD supplements in sub-clinical

VitD deficiency. However, we acknowledge that the present study does not provide sufficient

data to draw rigorous evidence-based conclusions with respect to treatment recommendations.

Our small pilot study is based on biomarker data rather than hard clinical outcomes. Future

research will be required to address these important clinical questions. Nevertheless, we believe

it is valuable to offer hypotheses based on implications derived from consideration of underlying

physiology and pathophysiology.

Comparisons among diagnostic criteria

We analyzed several possible indices of VitD status to determine the degree of overlap between

data obtained before and after VitD3 supplements (Fig. S1):

- 435 • 25(OH)D and 24,25(OH)$_2$D: No overlap was observed between the two data sets (i.e., before
- 436 versus after administration of VitD3 supplements) for total levels of 25(OH)D (both Quest
- 437 and Heartland assays) (Fig. S1A and S1B) or 24,25(OH)$_2$D (Figs. S1C).
- 438 • 1,25(OH)$_2$D/24,25(OH)$_2$D ratio: Participants (#9 and #10) with screening 25(OH)D levels
- 439 <20 ng/mL, exhibited baseline ratios of 1,25(OH)$_2$D/24,25(OH)$_2$D and
- 440 25(OH)D/1,25(OH)$_2$D that overlapped with the range of ratios observed after they had
- 441 received VitD3 supplements (Figs. S1D and S1E). We hypothesize that this overlap of data is
- 442 explained by the fact that these two participants were likely VitD sufficient at baseline and
- 443 that they had been misclassified based on measurements of total 25(OH)D levels.
- 444 • 24,25(OH)$_2$D/25(OH)D ratio. The 24,25(OH)$_2$D/25(OH)D ratio had a greater degree of
- 445 overlap; six of eleven "VitD deficient" participants [i.e., 25(OH)D <20 ng/mL] exhibited
- 446 24,25(OH)$_2$D/25(OH)D ratios within the range observed in participants who had received
- 447 VitD3 supplements. We hypothesize that the extensive degree of data overlap suggests that
- 448 the 24,25(OH)$_2$D/25(OH)D ratio may not provide the optimal index to assess VitD status in
- 449 individual patients.

Taken together, our pilot data suggest that two ratios may be more effective as indices to

diagnose VitD deficiency: 1,25(OH)$_2$D/24,25(OH)$_2$D and 25(OH)D/1,25(OH)$_2$D. The

1,25(OH)$_2$D/24,25(OH)$_2$D ratio has the theoretical advantage that it explicitly includes a

measurement of 24,25(OH)$_2$D and, therefore, directly reflects 24-hydroxylase activity – a key

homeostatic regulator. In contrast, the 25(OH)D/1,25(OH)$_2$D ratio has the practical advantage

that assays for both 25(OH)D and 1,25(OH)$_2$D are widely available and less expensive than

assays for 24,25(OH)$_2$D.

 Improved assessment of VitD status: an unmet need

In a recent editorial, Cummings & Rosen (2) questioned the value of screening the general

population for VitD deficiency. Nevertheless, they emphasized that there are specific populations

in whom screening would be valuable – including, people with malabsorption (e.g.,

inflammatory bowel disease), older people living in residential facilities who may not be exposed

to sunlight, and people with osteoporosis. People with chronic kidney disease also fall into the

group who may benefit from improved clinical assessment of VitD status. Based on the totality

of evidence, we conclude that measurement of total levels of 25(OH)D does not provide optimal

assessment of clinical VitD status. From a scientific perspective, ideal diagnostic biomarkers

would address two critical challenges: (a) minimization of the confounding influence of variation

in VDBP levels; and (b) integrating the "wisdom of the body" by reflecting the degree of

activation of physiological homeostatic mechanisms. VitD metabolite ratios have potential to

address both challenges. Future research will be required to fully assess the performance of this

innovative precision diagnostics approach to assessment of VitD status.

ACKNOWLEDGEMENTS

The authors gratefully acknowledge research funding provided by NIDDK and the NIH Office of Dietary Supplements: R01DK118942, R01DK118942-02S1, and T32DK098107. We are also grateful to the staff at University of Maryland's Amish Research Clinic and to the members of the Old Order Amish Community in Lancaster, PA who participated in this clinical trial.

AUTHORS' CONTRIBUTIONS

Conception of the clinical trial and PI for NIH grant (R01DK118942-02S1): SIT and ALB

Acquisition and analysis of data: ALB, H-RC, MEM, EAS, SIT, HBW, ZSY

Preparation of first draft of manuscript: ZSY and SIT

Revising and approving final version of manuscript: all authors

Accountability for all aspects of work: SIT

DATA AVAILABILITY

Primary data will be made available upon request to qualified academic investigators for research purposes under a Data Transfer Agreement to protect research participants' confidential information.

491 **Table 1. Goodness of fit for mathematical model equations**. The Table includes metrics for

492 the goodness of fit for the modeling equations for $1,25(OH)_2D$ (Fig. 2A) and $24,25(OH)_2D$ (Fig.

493 2B) as well as the goodness of fit for modeling of three vitamin D metabolite ratios (Figs. 4A,

494 5A, and 5B).

	$24,25(OH)D$	$1,25(OH)_2D$	$1,25(OH)_2D/$ $24,25(OH)_2D$	$25(OH)D/$ $1,25(OH)_2D$	$24,25(OH)_2D/$ $25(OH)D$
Sum of squares due to regression (SSR) [a]	113	315	809	3.37	0.150
Total sum of squares about mean (SST) [b]	105	3341	849	3.22	0.151
Sum of squared errors (SSE) [c]	8.2	3483	412	1.66	0.079
Ratio of SSE/SST	0.078	1.04	0.49	0.52	0.52
Ratio of SSR/SST	1.08	0.094	0.95	1.05	0.995

[a] $SSR = \sum(\hat{x}_i - \bar{x})^2$

[b] $SST = \sum(x_i - \bar{x})^2$

[c] $SSE = \sum(x_i - \hat{x}_i)^2$

Where x_i represents individual observed total levels of VitD metabolites, $\hat{x}_i$ represents

individual predicted total levels of VitD metabolites, and $\bar{x}$ represents the mean of observed total

levels of VitD metabolites.

Table 2. Three research participants exemplifying impact of precision diagnostics strategy

for diagnosis of VitD deficiency. This Table summarizes selected laboratory data and calculated

VitD metabolite ratios for participant #11 – the participant exhibiting the highest level of the

$1,25(OH)_2D/24,25(OH)_2D$ ratio observed in our clinical trial (8). Participants #6 and #9 were

selected as matches for participant #11 based on having similar baseline total levels of plasma

25(OH)D.

Participant	#9	#6	#11
Baseline 25(OH)D (ng/mL)	12.3	10.8	11.7
Baseline 24,25(OH)$_2$D (ng/mL)	0.9	0.8	0.5
Baseline 1,25(OH)$_2$D (pg/mL)	19	33	51
Baseline PTH (pg/mL	51	29	62
Baseline FGF23 (pg/mL)	57	60	50
[1,25(OH)$_2$D] / [24,25(OH)$_2$D]	20	41	110
[25(OH)D] / [1,25(OH)$_2$D]	0.65	0.33	0.23
[24,25(OH)$_2$D] / [25(OH)D]	0.076	0.075	0.040
PTH: response to VitD3	+5%	+3%	-34%
Participants' VitD status based on the "Endocrine Society" guideline	VitD deficient	VitD deficient	VitD deficient
Participants' clinical classification using [1,25(OH)$_2$D] / [24,25(OH)$_2$D] ratio	VitD Sufficiency	Sub-clinical VitD deficiency	Overt VitD deficiency

  FIGURE LEGENDS

Figure 1. Impact of VitD3 supplementation on total levels of VitD metabolites. Healthy

participants (N=11) were recruited based on meeting the Endocrine Society's criterion of VitD

deficiency [25(OH)D ≤20 ng/mL]. Total levels of VitD metabolites were assayed before and

after participants received VitD3 supplements (8): 25(OH)D (panel A), 24,25(OH)$_2$D (panel B),

and 1,25(OH)$_2$D (panel C). Data are presented as means ± SEM; p-values were calculated using

a two-tailed t-test for paired data.

Figure 2. Total levels of 1,25(OH)$_2$D and 24,25(OH)$_2$D as a function of total levels of

25(OH)D. Panels A and B present pooled data for individual participants when they were VitD

deficient (gray circles) and after they received VitD3 supplements (black circles). 1,25(OH)$_2$D

(panel A) and 24,25(OH)$_2$D (panel B) are plotted as a function of total levels of 25(OH)D. The

text box in panel B presents the Spearman correlation coefficient. The curves represent the

equations derived from our mathematical model: equation (1) in Panel A and equation (7) in

Panel B. Values of parameters for Equation (1): $W_{24}=8$ ng/mL; $L_{24}=40$ ng/mL; and $\alpha=0.1$.

Values for parameters for Equation (7): $W_{1,25}=40$ ng/mL; $L_{1,25}=60$ ng/mL; $V_1=40$; $K=60$ ng/mL;

$\alpha=.0.1$; and $m_{1,25}=1$.

Figure 3. Assumptions underlying mathematical model: regulation of 24-hydroxylase

activity in response to clinical VitD status. Panel A depicts curves corresponding to equations

(1) and (2) [sigmoid and hyperbola, respectively]. Panel B depicts a family of hyperbolas

[equation (2)] corresponding to varying degrees of induction from 10-100% of maximal

induction of 24-hydroxylase activity. Panel C depicts equation (3), which is the fractional

induction of 24-hydroxylase activity relative to the maximal level of induction as a function of

25(OH)D. Values of parameters for Equation (1): W_{24}=8 ng/mL; L_{24}=40 ng/mL; and a=.0.1.

Values for parameters for Equation (2): V_{24}=10 and K_{24}=20 ng/mL. Values of parameters for

Equation (3) m(24,25)=1; other parameters the same as for Equations (1) and (2).

Figure 4. The 1,25(OH)₂D/24,25(OH)D and 25(OH)D/1,25(OH)₂D ratios reflect clinical

VitD status. The graphs summarize data from individual participants when they were VitD

deficient (gray circles) and after they received VitD3 supplements (black circles). Panel A

depicts the 1,25(OH)₂D/24,25(OH)₂D ratio as a function of total 25(OH)D. The modeled curve

was calculated as the ratio of modeled values for 1,25(OH)₂D [equation (7)] divided by modeled

values of 24,25(OH)₂D [equation (1)]. Panel B depicts 1,25(OH)₂D/24,25(OH)₂D ratio as a

function of 25(OH)D/1,25(OH)₂D ratio. The fitted curves were calculated by Graph Pad Prism

software. Text boxes indicate Spearman correlation coefficients and p-values for the correlations.

Figure 5. VitD metabolite ratios [25(OH)D/1,25(OH)$_2$D and 24,25(OH)$_2$D/25(OH)D] as a

function of the total levels of 25(OH)D. The graphs summarize data from individual

participants when they were VitD deficient (gray circles) and after they received VitD3

supplements (black circles). Panel A depicts the 25(OH)D/1,25(OH)$_2$D ratio as a function of

total 25(OH)D. The modeled curve was calculated as a linear regression using Graph Pad Prism

software. Panel B depicts 24,25(OH)$_2$D/25(OH)D ratio as a function of 25(OH)D. The modeled

curve was calculated as modeled values for 24,25(OH)$_2$D [equation (1)] divided by assumed

values of 25(OH)D.

Figure S1. Individual level data for six potential indices of clinical VitD status: effect of

VitD supplementation. Total levels of VitD metabolites were assayed before and after

participants received VitD3 supplements (8). Individual participants' data are plotted as follows:

25(OH)D assayed at Quest Diagnostics (panel A); 25(OH)D assayed at Heartland Assays (panel

B); 24,25(OH)$_2$D (panel C); the 1,25(OH)$_2$D/24,25(OH)$_2$D ratio (panel D); the

25(OH)D/1,25(OH)$_2$D ratio (panel E); the 24,25(OH)$_2$D/25(OH)D ratio (panel F). Individual

participants were classified as VitD deficient (solid black symbols), VitD insufficient (solid gray

symbols), or VitD sufficient (open symbols) based on published diagnostic criteria for the

1,25(OH)$_2$D/24,25(OH)$_2$D ratio (11): VitD deficient (ratio $\geq$51), VitD insufficient (ratio = 35-

50), or VitD sufficient (ratio <35).

REFERENCES:

1.   Bouillon R, Manousaki D, Rosen C, Trajanoska K, Rivadeneira F, and Richards JB. The

health effects of vitamin D supplementation: evidence from human studies. *Nat Rev*

Endocrinol. 2022;18(2):96-110.

2.   Cummings SR, and Rosen C. VITAL Findings - A Decisive Verdict on Vitamin D

Supplementation. *N Engl J Med.* 2022;387(4):368-70.

3.   LeBoff MS, Chou SH, Ratliff KA, Cook NR, Khurana B, Kim E, et al. Supplemental

Vitamin D and Incident Fractures in Midlife and Older Adults. *N Engl J Med.*

2022;387(4):299-309.

4.   Pfotenhauer KM, and Shubrook JH. Vitamin D Deficiency, Its Role in Health and Disease,

and Current Supplementation Recommendations. *J Am Osteopath Assoc.* 2017;117(5):301-

5.

5.   Christakos S, Dhawan P, Porta A, Mady LJ, and Seth T. Vitamin D and intestinal calcium

absorption. *Mol Cell Endocrinol.* 2011;347(1-2):25-9.

6.   Young K, Beggs MR, Grimbly C, and Alexander RT. Regulation of 1 and 24 hydroxylation

of vitamin D metabolites in the proximal tubule. *Exp Biol Med (Maywood).*

2022;247(13):1103-11.

7.   Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al.

Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society

clinical practice guideline. *J Clin Endocrinol Metab.* 2011;96(7):1911-30.

8.   Yazdi ZS, Streeten EA, Whitlatch HB, Montasser ME, Beitelshees AL, and Taylor SI.

Vitamin D deficiency increases vulnerability to canagliflozin-induced adverse effects on

1,25-dihydroxyvitamin D and PTH. *medRxiv.* 2023.

9.   Shieh A, Ma C, Chun RF, Wittwer-Schegg J, Swinkels L, Huijs T, et al. Associations

Between Change in Total and Free 25-Hydroxyvitamin D With 24,25-Dihydroxyvitamin

D and Parathyroid Hormone. *J Clin Endocrinol Metab.* 2018;103(9):3368-75.

10. Holick MF. Vitamin D status: measurement, interpretation, and clinical application. *Ann*

Epidemiol. 2009;19(2):73-8.

11. Tang JCY, Jackson S, Walsh NP, Greeves J, and Fraser WD. The dynamic relationships

between the active and catabolic vitamin D metabolites, their ratios, and associations with

PTH. *Sci Rep.* 2019;9(1):6974.

12. Ahmed LHM, Butler AE, Dargham SR, Latif A, Chidiac OM, Atkin SL, et al. Vitamin

D(3) metabolite ratio as an indicator of vitamin D status and its association with diabetes

complications. *BMC Endocr Disord.* 2020;20(1):161.

13. Bansal N, Katz R, Appel L, Denburg M, Feldman H, Go AS, et al. Vitamin D Metabolic

Ratio and Risks of Death and CKD Progression. *Kidney Int Rep.* 2019;4(11):1598-607.

14. Ginsberg C, Katz R, de Boer IH, Kestenbaum BR, Chonchol M, Shlipak MG, et al. The

24,25 to 25-hydroxyvitamin D ratio and fracture risk in older adults: The cardiovascular

health study. *Bone.* 2018;107:124-30.

15. Meng L, Su C, Shapses SA, and Wang X. Total and free vitamin D metabolites in patients

with primary hyperparathyroidism. *J Endocrinol Invest.* 2022;45(2):301-7.

16. Batacchi Z, Robinson-Cohen C, Hoofnagle AN, Isakova T, Kestenbaum B, Martin KJ, et

al. Effects of Vitamin D(2) Supplementation on Vitamin D(3) Metabolism in Health and

CKD. *Clin J Am Soc Nephrol.* 2017;12(9):1498-506.

17. Schlingmann KP, Kaufmann M, Weber S, Irwin A, Goos C, John U, et al. Mutations in

CYP24A1 and idiopathic infantile hypercalcemia. *N Engl J Med.* 2011;365(5):410-21.

18.   Streeten EA, Zarbalian K, and Damcott CM. CYP24A1 mutations in idiopathic infantile

633   hypercalcemia. *N Engl J Med.* 2011;365(18):1741-2; author reply 2-3.

634   19.   Robinson-Cohen C, Zelnick LR, Hoofnagle AN, Lutsey PL, Burke G, Michos ED, et al.

635   Associations of Vitamin D-Binding Globulin and Bioavailable Vitamin D Concentrations

636   With Coronary Heart Disease Events: The Multi-Ethnic Study of Atherosclerosis (MESA).

637   *J Clin Endocrinol Metab.* 2017;102(8):3075-84.

638   20.   Ginsberg C, Hoofnagle AN, Katz R, Becker JO, Kritchevsky SB, Shlipak MG, et al. The

639   Vitamin D Metabolite Ratio Is Independent of Vitamin D Binding Protein Concentration.

640   *Clin Chem.* 2021;67(2):385-93.

641   21.   Ginsberg C, Hoofnagle AN, Katz R, Hughes-Austin J, Miller LM, Becker JO, et al. The

642   Vitamin D Metabolite Ratio Is Associated With Changes in Bone Density and Fracture

643   Risk in Older Adults. *J Bone Miner Res.* 2021;36(12):2343-50.

644   22.   Davies KJ. Adaptive homeostasis. *Mol Aspects Med.* 2016;49:1-7.

645   23.   Cannon WB. *The wisdom of the body.* Norton and Company Limited, W. W.; 1963.

646   24.   Brenza HL, Kimmel-Jehan C, Jehan F, Shinki T, Wakino S, Anazawa H, et al. Parathyroid

647   hormone activation of the 25-hydroxyvitamin D3-1alpha-hydroxylase gene promoter. *Proc*

648   *Natl Acad Sci U S A.* 1998;95(4):1387-91.

649   25.   Jesudason D, Need AG, Horowitz M, O'Loughlin PD, Morris HA, and Nordin BE.

650   Relationship between serum 25-hydroxyvitamin D and bone resorption markers in vitamin

651   D insufficiency. *Bone.* 2002;31(5):626-30.

652   26.   Rosen CJ, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, et al. IOM

653   committee members respond to Endocrine Society vitamin D guideline. *J Clin Endocrinol*

654   *Metab.* 2012;97(4):1146-52.

655   27.   Jones G. 100 YEARS OF VITAMIN D: Historical aspects of vitamin D. *Endocr Connect.*

656   2022;11(4).

657   28.   Demay MB. The good and the bad of vitamin D inactivation. *J Clin Invest.*

658   2018;128(9):3736-8.

659   29.   Martineau C, Kaufmann M, Arabian A, Jones G, and St-Arnaud R. Preclinical safety and

660   efficacy of 24R,25-dihydroxyvitamin D(3) or lactosylceramide treatment to enhance

661   fracture repair. *J Orthop Translat.* 2020;23:77-88.

662   30.   Martineau C, Naja RP, Husseini A, Hamade B, Kaufmann M, Akhouayri O, et al. Optimal

663   bone fracture repair requires 24R,25-dihydroxyvitamin D3 and its effector molecule

664   FAM57B2. *J Clin Invest.* 2018;128(8):3546-57.

665   31.   Meyer MB, and Pike JW. Mechanistic homeostasis of vitamin D metabolism in the kidney

666   through reciprocal modulation of Cyp27b1 and Cyp24a1 expression. *J Steroid Biochem*

667   *Mol Biol.* 2020;196:105500.

668   32.   Blau JE, Bauman V, Conway EM, Piaggi P, Walter MF, Wright EC, et al. Canagliflozin

669   triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a

670   randomized crossover study. *JCI Insight.* 2018;3(8).

671   33.   el-Hajj Fuleihan G, Klerman EB, Brown EN, Choe Y, Brown EM, and Czeisler CA. The

672   parathyroid hormone circadian rhythm is truly endogenous--a general clinical research

673   center study. *J Clin Endocrinol Metab.* 1997;82(1):281-6.

674   34.   Kawai M, Kinoshita S, Shimba S, Ozono K, and Michigami T. Sympathetic activation

675   induces skeletal Fgf23 expression in a circadian rhythm-dependent manner. *J Biol Chem.*

676   2014;289(3):1457-66.

35. Bikle DD. The Free Hormone Hypothesis: When, Why, and How to Measure the Free

Hormone Levels to Assess Vitamin D, Thyroid, Sex Hormone, and Cortisol Status. *JBMR*

Plus. 2021;5(1):e10418.

36. Lemoine S, Figueres L, Bacchetta J, Frey S, and Dubourg L. Calcium homeostasis and

hyperparathyroidism: Nephrologic and endocrinologic points of view. *Ann Endocrinol*

(Paris). 2022;83(4):237-43.

37. Ladenson PW. Diseases of the thyroid gland. *Clin Endocrinol Metab.* 1985;14(1):145-73.